We are live on ! Find out more
CYTK icon

Cytokinetics
CYTK

343 hedge funds and large institutions have $7.34B invested in Cytokinetics in 2024 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 156 increasing their positions, 92 reducing their positions, and 86 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more repeat investments, than reductions

Existing positions increased: 156 | Existing positions reduced: 92

54% more call options, than puts

Call options by funds: $199M | Put options by funds: $130M

3.79% more ownership

Funds ownership: 114.35% → 118.14% (+3.8%)

9% less funds holding in top 10

Funds holding in top 10: 22 → 20 (-2)

11% less capital invested

Capital invested by funds: $8.26B → $7.34B (-$919M)

12% less funds holding

Funds holding: 390 → 343 (-47)

50% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 86

Holders
343
Holders Change
-47
Holders Change %
-12.05%
% of All Funds
4.95%
Holding in Top 10
20
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-9.09%
% of All Funds
0.29%
New
43
Increased
156
Reduced
92
Closed
86
Calls
$199M
Puts
$130M
Net Calls
+$69.5M
Net Calls Change
+$46.6M

Top Buyers

1
DGM
Darwin Global Management
Jersey
+$276M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$213M
3
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$182M
4
BlackRock
BlackRock
New York
+$136M
5
State Street
State Street
Massachusetts
+$122M

Top Sellers

1
Marshall Wace
Marshall Wace
United Kingdom
-$53M
2
Invesco
Invesco
Georgia
-$49.6M
3
Millennium Management
Millennium Management
New York
-$48.9M
4
LCM
Laurion Capital Management
New York
-$36.5M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$34.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$795M +$136M +2,258,006 +18%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$624M +$37.5M +621,985 +6%
Vanguard Group
3
Vanguard Group
Pennsylvania
$620M +$87M +1,440,620 +14%
T. Rowe Price Investment Management
4
T. Rowe Price Investment Management
Maryland
$441M +$182M +3,017,088 +59%
Wellington Management Group
5
Wellington Management Group
Massachusetts
$407M +$213M +3,528,070 +89%
State Street
6
State Street
Massachusetts
$355M +$122M +2,028,178 +45%
DGM
7
Darwin Global Management
Jersey
$246M +$276M +4,575,558 New
Bank of America
8
Bank of America
North Carolina
$237M -$24M -396,859 -8%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$148M +$29.7M +491,481 +22%
RI
10
RTW Investments
New York
$147M +$11.8M +196,078 +8%
PCH
11
Polar Capital Holdings
United Kingdom
$133M +$51.3M +849,089 +53%
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$128M -$34.6M -572,605 -20%
BC
13
Boxer Capital
California
$114M – – –
VPC
14
Vestal Point Capital
New York
$112M -$4.53M -75,000 -3%
AC
15
Armistice Capital
New York
$112M +$32.6M +540,303 +35%
AllianceBernstein
16
AllianceBernstein
Tennessee
$102M +$6.59M +109,096 +6%
Pictet Asset Management
17
Pictet Asset Management
Switzerland
$95.8M +$876K +14,516 +0.8%
PHS
18
PFM Health Sciences
California
$95.2M – – –
Marshall Wace
19
Marshall Wace
United Kingdom
$90.9M -$53M -878,644 -34%
MAM
20
Melqart Asset Management
United Kingdom
$90.8M +$41.8M +692,390 +70%
Northern Trust
21
Northern Trust
Illinois
$69.5M +$10.3M +171,453 +15%
Goldman Sachs
22
Goldman Sachs
New York
$61.7M +$27M +446,705 +65%
PCM
23
Pentwater Capital Management
Florida
$60.6M +$2.35M +39,000 +4%
JP Morgan Chase
24
JP Morgan Chase
New York
$60.2M +$25.6M +423,839 +62%
SCM
25
Sarissa Capital Management
Connecticut
$60.1M +$48.9M +810,000 +270%
1
2 3 4 5

CYTK Hedge Fund Activity: Q2 2024 in Review

343 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2024, worth a combined $7.34B — down 11% from $8.26B a quarter earlier.

Sellers outnumbered buyers: 86 funds closed out of CYTK and 43 opened new positions — a net loss of 43 holders — while 92 trimmed existing stakes and 156 added.

The largest buyer was Darwin Global Management, opening a new position worth an estimated $276M. The largest seller was Marshall Wace, cutting an estimated $53M.

  • 343 institutional investors held Cytokinetics (CYTK) as of Q2 2024, down from 390 in Q1 2024.
  • Funds reported $7.34B of Cytokinetics stock for Q2 2024, down 11% quarter-over-quarter.
  • 43 funds opened new Cytokinetics positions in Q2 2024 and 86 closed out, a net change of -43 holders.
  • The largest Cytokinetics buyer in Q2 2024 was Darwin Global Management, an estimated $276M added.
  • The largest Cytokinetics seller in Q2 2024 was Marshall Wace, an estimated $53M sold.

Based on aggregated 13F filings for Q2 2024.